Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients

Trastuzumab deruxtecan (T-DXd), a human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC), has altered the treatment landscape in breast cancer (BC), irrespective of the HR-receptor status. The use of the agent is increasing, despite the finding that exposure to T-DXd...

Descripción completa

Detalles Bibliográficos
Autores principales: Wekking, D., Porcu, M., Pellegrino, B., Lai, E., Mura, G., Denaro, N., Saba, L., Musolino, A., Scartozzi, M., Solinas, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679891/
https://www.ncbi.nlm.nih.gov/pubmed/37951130
http://dx.doi.org/10.1016/j.esmoop.2023.102043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679891/
https://www.ncbi.nlm.nih.gov/pubmed/37951130
http://dx.doi.org/10.1016/j.esmoop.2023.102043

Ejemplares similares